FRUZAQLA^® (fruquintinib) patient resources

Patient resources are available to help your patients and their caregivers

We help patients continue their journey with FRUZAQLA by providing helpful educational resources.

Patient Brochure

Information for patients who are taking FRUZAQLA

Download the brochure

Dosing Calendar

Help your patients track their treatment schedule

Discover the dosing calendar

Takeda Oncology Here2Assist^® Enrollment Form

An interactive PDF to help your patients get started with Takeda Oncology Here2Assist^®

Download the PDF

Additional resources for your patients can be found on the FRUZAQLA patient website.

Share these additional metastatic colorectal cancer patient resources, including colorectal cancer support groups, with your patients

Besides the support patients will receive from their oncology team, there may be additional supportive resources available. Encourage your patients to become even more active in their care by reaching out and finding the people, tools, and educational resources that they may need.

COLONTOWN a community of more than 100 private groups on Facebook for colorectal cancer patients and care partners.
Colon Cancer Coalition works to increase access to screenings and educate the public about signs and symptoms of colorectal cancer.
Colorectal Cancer Alliance advocates for prevention, magnifies patient support, and accelerates research to end colorectal cancer.
Global Colon Cancer Association helps patients get fair access to necessary colon cancer and colorectal treatments, screenings, and more.
Fight Colorectal Cancer provides balanced and objective information on colon and rectal cancer research, treatment, and policy.
Say Yes to Hope provides resources, information, support, and hope to all those who are affected by advanced cancer.

Takeda Oncology is not affiliated with any of these organizations. By listing these resources, Takeda Oncology is not endorsing any particular service or group and we are not responsible for the content of these sites or services. They are provided here for informational purposes and are not meant to replace the medical advice of a healthcare provider.

Takeda Oncology Here2Assist^® Patient Support Program

We're here to help your patients with their coverage, financial, and educational resource needs.

Get program details

Resources for Healthcare Professionals

Tools to help support your patients with mCRC.

Find support and resources

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hypertension occurred in 49% of 911 patients with mCRC treated with FRUZAQLA, including Grade 3-4 events in 19%, and hypertensive crisis in three patients (0.3%). Do not initiate FRUZAQLA unless blood pressure is adequately controlled. Monitor blood pressure weekly for the first month and at least monthly thereafter as clinically indicated. Initiate or adjust anti-hypertensive therapy as appropriate. Withhold, reduce dose, or permanently discontinue FRUZAQLA based on severity of hypertension.

Hemorrhagic Events including serious, fatal events can occur with FRUZAQLA. In 911 patients with mCRC treated with FRUZAQLA, 6% of patients experienced gastrointestinal hemorrhage, including 1% with a Grade ≥3 event and 2 patients with fatal hemorrhages. Permanently discontinue FRUZAQLA in patients with severe or life-threatening hemorrhage. Monitor the International Normalized Ratio (INR) levels in patients receiving anticoagulants.

Infections. FRUZAQLA can increase the risk of infections, including fatal infections. In 911 patients with mCRC treated with FRUZAQLA, the most common infections were urinary tract infections (6.8%), upper respiratory tract infections (3.2%) and pneumonia (2.5%); fatal infections included pneumonia (0.4%), sepsis (0.2%), bacterial infection (0.1%), lower respiratory tract infection (0.1%), and septic shock (0.1%). Withhold FRUZAQLA for Grade 3 or 4 infections, or worsening infection of any grade. Resume FRUZAQLA at the same dose when the infection has resolved.

Gastrointestinal Perforation occurred in patients treated with FRUZAQLA. In 911 patients with mCRC treated with FRUZAQLA, 1.3% experienced a Grade ≥3 gastrointestinal perforation, including one fatal event. Permanently discontinue FRUZAQLA in patients who develop gastrointestinal perforation or fistula.

Hepatotoxicity. FRUZAQLA can cause liver injury. In 911 patients with mCRC treated with FRUZAQLA, 48% experienced increased ALT or AST, including Grade ≥3 events in 5%, and fatal events in 0.2% of patients. Monitor liver function tests (ALT, AST, and bilirubin) before initiation and periodically throughout treatment with FRUZAQLA. Temporarily hold and then reduce or permanently discontinue FRUZAQLA depending on the severity and persistence of hepatotoxicity as manifested by elevated liver function tests.

Proteinuria. FRUZAQLA can cause proteinuria. In 911 patients with mCRC treated with FRUZAQLA, 36% experienced proteinuria and 2.5% of patients experienced Grade ≥3 events. Monitor for proteinuria before initiation and periodically throughout treatment with FRUZAQLA. For proteinuria ≥2g/24 hours, withhold FRUZAQLA until improvement to ≤Grade 1 proteinuria and resume FRUZAQLA at a reduced dose. Discontinue FRUZAQLA in patients who develop nephrotic syndrome.

Palmar-Plantar Erythrodysesthesia (PPE) occurred in 35% of 911 patients treated with FRUZAQLA, including 8% with Grade 3 events. Based on severity of PPE, withhold FRUZAQLA and then resume at the same or reduced dose.

Posterior Reversible Encephalopathy Syndrome (PRES), a syndrome of subcortical vasogenic edema diagnosed by characteristic finding on MRI, occurred in one of 911 patients treated with FRUZAQLA. Perform an evaluation for PRES in any patient presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Discontinue FRUZAQLA in patients who develop PRES.

Impaired Wound Healing. In 911 patients with mCRC treated with FRUZAQLA, 1 patient experienced a Grade 2 event of wound dehiscence. Do not administer FRUZAQLA for at least 2 weeks prior to major surgery. Do not administer FRUZAQLA for at least 2 weeks after major surgery and until adequate wound healing. The safety of resumption of FRUZAQLA after resolution of wound healing complications has not been established.

Arterial Thromboembolic Events. In 911 patients with mCRC treated with FRUZAQLA, 0.8% of patients experienced an arterial thromboembolic event. Initiation of FRUZAQLA in patients with a recent history of thromboembolic events should be carefully considered. In patients who develop arterial thromboembolism, discontinue FRUZAQLA.

Allergic Reactions to FD&C Yellow No. 5 (Tartrazine) and No. 6 (Sunset Yellow FCF). FRUZAQLA 1 mg capsules contain FD&C Yellow No. 5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. FRUZAQLA 1 mg contains FD&C Yellow No. 6 (sunset yellow FCF), which may cause allergic reactions.

Embryo-Fetal Toxicity. Based on findings in animal studies and its mechanism of action, FRUZAQLA can cause fetal harm when administered to pregnant women. Advise pregnant women of the potential risk to a fetus. Advise females of childbearing potential and males with female partners of childbearing potential to use effective contraception during treatment with FRUZAQLA and for 2 weeks after the last dose.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥20%) following treatment with FRUZAQLA included hypertension, palmar-plantar erythrodysesthesia (hand-foot skin reactions), proteinuria, dysphonia, abdominal pain, diarrhea, and asthenia.

DRUG INTERACTIONS

Avoid concomitant administration of FRUZAQLA with strong or moderate CYP3A inducers.

USE IN SPECIFIC POPULATIONS

Lactation: Advise women not to breastfeed during treatment with FRUZAQLA and for 2 weeks after the last dose.

To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-844-662-8532 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see FRUZAQLA (fruquintinib) full Prescribing Information.

FRUZAQLA^® (fruquintinib) patient resources

Patient resources are available to help your patients and their caregivers

Patient Brochure

Dosing Calendar

Takeda Oncology Here2Assist^® Enrollment Form

Share these additional metastatic colorectal cancer patient resources, including colorectal cancer support groups, with your patients

Takeda Oncology Here2Assist^® Patient Support Program

Resources for Healthcare Professionals

IMPORTANT SAFETY INFORMATION AND INDICATION

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

DRUG INTERACTIONS

USE IN SPECIFIC POPULATIONS

INDICATION

Patient resources are available to help your patients and their caregivers

Patient Brochure

Dosing Calendar

Takeda Oncology Here2Assist® Enrollment Form

Share these additional metastatic colorectal cancer patient resources, including colorectal cancer support groups, with your patients

Takeda Oncology Here2Assist® Patient Support Program

Resources for Healthcare Professionals

IMPORTANT SAFETY INFORMATION AND INDICATION

Takeda Oncology Here2Assist^® Enrollment Form

Takeda Oncology Here2Assist^® Patient Support Program